Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label mass balance and pharmacokinetics study of 14C-ESN-364 in healthy postmenopausal women
NL-OMON46563Phase 1Active, not recruiting
- Sponsor
- Ogeda
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fezolinetant in vasomotor symptoms, endometriosis, polycystic ovary syndrome (PCOS) and 1 more, sponsored by Ogeda. Primary endpoints: Pharmacokinetics of ESN-364 and total radioactivity and Mass balance of total radioactivity. Started Mar 2018; status: active, not recruiting.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptomsendometriosispolycystic ovary syndrome (PCOS)Fibromyoma (LM)
Beyond the preview
Go deeper on NL-OMON46563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46563.